Supernus Pharma (SUPN) Misses Q2 EPS by 8c, provides guidance

Supernus Pharma (NASDAQ: SUPN) reported Q2 EPS of $0.40, $0.08 worse than the analyst estimate of $0.48. Revenue for the quarter came in at $165.5 million versus the consensus estimate of $154.3 million.

GUIDANCE:

Supernus Pharma sees FY 2025 revenue of $670-700 million, versus the consensus of $636.4 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
• Berenberg Starts Natwest Group PLC (NWG:LN) (NWG) at Buy
• Axis Capital Limited Downgrades Tech Mahindra Ltd. (TECHM:IN) to Sell (4)